# Cross-session log — Wave 1 follow-ups — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director`)

Condensed log — full verbatim message text is long; content has already been distributed into
`02_SOURCE-INVENTORY.md`, `03_DECISION-LOG.md`, and `04_OPEN-QUESTIONS.md`. This entry records
that the exchanges happened and where their content landed.

## guideline-risk-intelligence — Wave 1 completion report (IN)

Reported `READY_FOR_INTEGRATION`: 11/11 assigned legacy citations verified (1 DOI error found),
full unread `Tonvasca_2026.md` remainder read (2 new citations + 4-citation adherence cluster
found), all 3 previously-unlocated guideline Search Protocol targets located, Sci-Hub compliance
concern on `mcp__research_hub__download_paper` raised and correctly handled. Pushed to
`origin/worktree-pit-eze-guideline-risk-wave1`.
→ Decisions 2026-08-31-08, 2026-08-31-09. `02_SOURCE-INVENTORY.md` rows #1,2,17,18,24,27–33,
new rows #34/#35, T-005/T-006/T-007 updated.

## Director reply (OUT)

Acknowledged, commended the Sci-Hub handling, logged both decisions, assigned T-009 to
safety-pharmacology, requested full citation strings, asked for clarification on the "second
compliance concern" phrasing.

## guideline-risk-intelligence — citation follow-up (IN)

Provided full formatted citations for #34, #35, T-005, T-006, T-007, and T-009 (T-009 explicitly
flagged as copied-not-verified). Clarified there was no second compliance concern — the ambiguous
sentence bundled the (already-resolved) Sci-Hub item with a purely informational note that
`research_hub`/`llamaparse` had reconnected since Wave 0.
→ `02_SOURCE-INVENTORY.md` fully updated with citation text; `04_OPEN-QUESTIONS.md` updated
(T-009 verification and T-006 duplicated-author-name flagged as open `NEEDS_ANALYST` items).

## trials-efficacy-intelligence — response to Director's 3 action items (IN)

(1) Provided full Crossref-sourced citations for Tsujita 2023 (T-004a) and Ako 2024 (T-004b).
(2) Acknowledged the research_hub restriction; disclosed one pre-restriction call to
`download_paper` (for citation #33) that returned nothing and involved no Sci-Hub content — no
policy violation, logged for transparency.
(3) Confirmed a local `git commit` (`62db3f3`) in its own worktree, on top of a pre-existing
environment checkpoint commit (`dc6ee2f`, authored "Dr Tseng") — no push attempted.
Also resolved the Director's "9 vs 3" bookkeeping question: the 9 TE-ids and the 3 not-located
legacy citations are non-overlapping counts drawn from different sets (4 located-legacy + 5
topic-notes-primary-trials/new-finds = 9; separately, 3 of the 7 assigned legacy citations were
not located and received no TE-id). No inconsistency, just under-explained originally.
→ `02_SOURCE-INVENTORY.md` T-004a/T-004b updated with full citations; `04_OPEN-QUESTIONS.md`
updated (research_hub disclosure and worktree-commit items marked resolved/no-action-needed).

## trials-efficacy-intelligence — closing acknowledgment (IN)

Added Q6 to its unresolved-questions.md: T-004a's abstract confirms the 4-arm design unambiguously
(N=293; pitavastatin 2mg/4mg/K-924 LD/K-924 HD) — no contradiction with the Director's earlier
title-framing observation — but the exact statistical comparison structure across arms (pooled vs.
pairwise) needs full-text before `40_SYNTHESIS/` cites dose-pair significance. Added the 9-vs-3
coverage breakdown to `search-log.md`. Committed locally (`fc9af43`, no push). Standing by.

## Director reply (OUT)

Acknowledged; no further action needed from trials-efficacy until Wave 2 dispatch or worktree
consolidation.

## Note

Both guideline-risk-intelligence and trials-efficacy-intelligence are now fully caught up and
standing by. Only safety-pharmacology-intelligence's Wave 1 completion report is still outstanding.
